Anti–PD-1–Related Pneumonitis during Cancer Immunotherapy | NEJM Skip to main content
NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a …

Cancer immunotherapy using immune-checkpoint blockade (ICB) has created a paradigm
shift in the treatment of advanced-stage cancers. The promising antitumour activity of …

Primary retroperitoneal neoplasms are a rare but diverse group of benign and malignant
tumors that arise within the retroperitoneal space but outside the major organs in this space. …

OBJECTIVE. The objectives of this article are to review the new Response Evaluation Criteria
in Solid Tumors (RECIST) guideline, version 1.1, highlighting the major changes in the …

Importance Programmed cell death 1 (PD-1) inhibitor–related pneumonitis is a rare but
clinically serious and potentially life-threatening adverse event. Little is known about its …

KRAS is the most common oncogenic driver in lung adenocarcinoma (LUAC). We previously
reported that STK11/LKB1 (KL) or TP53 (KP) comutations define distinct subgroups of …

Purpose: Immune-related response criteria (irRC) was developed to adequately assess
tumor response to immunotherapy. The irRC are based on bidimensional measurements, as …

Background Cigarette smoking is associated with emphysema and radiographic interstitial
lung abnormalities. The degree to which interstitial lung abnormalities are associated with …

Targeted therapies have demonstrated efficacy against specific subsets of molecularly defined
cancers 1 , 2 , 3 , 4 . Although most patients with lung cancer are stratified according to a …

Purpose: Investigate the clinical characteristics, radiographic patterns, and treatment course
of PD-1 inhibitor–related pneumonitis in advanced cancer patients. Experimental Design: …